SEG101B2201: A phase 2, Multicenter, Open-Label Study to AssessAppropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle